Literature DB >> 23660419

Management of hepatitis B: our practice and how it relates to the guidelines.

Suna Yapali1, Nizar Talaat1, Anna S Lok2.   

Abstract

Seven drugs have been approved for the treatment of chronic hepatitis B. Antiviral treatment has been shown to be effective in suppressing hepatitis B virus replication, decreasing inflammation and fibrosis in the liver, and preventing progression of liver disease. However, current medications do not eradicate hepatitis B virus; therefore, a key question is which patients need to start treatment and which patients can be monitored. Professional societies have developed guidelines to assist physicians in recognition, diagnosis, and optimal management of patients with chronic hepatitis B. These guidelines suggest preferred approaches, and physicians are expected to exercise clinical judgment to determine the most appropriate management based on the circumstances of the individual patient. This article reviews recommendations in hepatitis B guidelines and the basis for those recommendations, and we discuss what we do in our practice to illustrate factors that may influence decisions regarding hepatitis B management.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AASLD; AFP; ALT; APASL; American Association for the Study of Liver Diseases; Antiviral Therapy; Asian Pacific Association for the Study of the Liver; CHB; Chronic Hepatitis B; EASL; European Association for the Study of the Liver; HBV; HBeAg; HBsAg; HCC; Hepatitis B Guidelines; IFN; Management; NUC; PEG-IFN; ULN; alanine aminotransferase; anti-HBc; anti-HBe; chronic hepatitis B; hepatitis B core antibody; hepatitis B e antibody; hepatitis B e antigen; hepatitis B surface antigen; hepatitis B virus; hepatocellular carcinoma; interferon; nucleos(t)ide analogue; pegylated-interferon; upper limit of normal; α-fetoprotein

Mesh:

Substances:

Year:  2013        PMID: 23660419     DOI: 10.1016/j.cgh.2013.04.036

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  36 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

2.  Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?

Authors:  Monica A Konerman; Anna S Lok
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-23       Impact factor: 11.382

3.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

Review 4.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

5.  Recurrent hepatocellular carcinoma: it's the virus!

Authors:  W Ray Kim; Gregory J Gores
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

Review 6.  Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

Authors:  Aleksei Suslov; Stefan Wieland; Stephan Menne
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

7.  Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.

Authors:  Kyu Sik Jung; Jun Yong Park; Young Eun Chon; Hyon-Suk Kim; Wonseok Kang; Beom Kyung Kim; Seung Up Kim; Do Young Kim; Kwang-Hyub Han; Sang Hoon Ahn
Journal:  J Gastroenterol       Date:  2015-12-19       Impact factor: 7.527

Review 8.  Chronic hepatitis B: A wave of new therapies on the horizon.

Authors:  Timothy M Block; Siddhartha Rawat; Carol L Brosgart
Journal:  Antiviral Res       Date:  2015-06-22       Impact factor: 5.970

9.  Characteristics of Pregnant Women With Hepatitis B Virus Infection in 5 US Public Health Jurisdictions, 2008-2012.

Authors:  Tanja Y Walker; Emily A Smith; Nancy Fenlon; Julie E Lazaroff; Cristina Dusek; Patrick Fineis; Susan A Crowley; Ruthie Benson; Steven L Veselsky; Trudy V Murphy
Journal:  Public Health Rep       Date:  2016-08-22       Impact factor: 2.792

10.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.